Features | Partner Sites | Information | LinkXpress
Sign In
JIB
European Federation of Biotechnology
BioConferenceLive

New High-Sensitivity Breath Analyzer Enables Wide Range Multi-Biomarker Identification

By BiotechDaily International staff writers
Posted on 06 May 2013
Image: Microscope/Micrograph of MEMS micro-heating element with integrated CMOS electronic driver and temperature sensing circuits (Photo courtesy of Cambridge CMOS Sensors).
Image: Microscope/Micrograph of MEMS micro-heating element with integrated CMOS electronic driver and temperature sensing circuits (Photo courtesy of Cambridge CMOS Sensors).
Scientists and engineers have developed a gas-sensing technology that could enable multiple diseases and other conditions to be diagnosed and monitored using a single, highly sensitive breath analyzer.

Thousands of chemical compounds are exhaled with every breath. The infrared emitter developed by Cambridge CMOS Sensors (CCMOSS; Cambridge, UK) is a low-power, low-cost device capable of identifying more than 35 biomarkers present in exhaled human breath in concentrations as low as 1 part per million. “Noninvasive breath analysis is an area of great potential for diagnosing and monitoring a wide range of medical conditions,” said Professor Florin Udrea of the Dept. of Engineering and CCMOSS’ CEO and cofounder; “Testing is easy and painless, and can be repeated as often as needed.”

A number of breath analysis tests are currently in the R&D phase, most of which use mass spectrometry or lasers to analyze the breath for specific compounds. However, these tests can detect only a small range of compounds, so different devices are needed to detect different conditions. The CCMOSS technology differs in that it uses broadband infrared radiation to make the detection of a wide range of biomarkers possible in a single device. The miniature heaters, or microhotplates, can be heated from room temperature to 700 °C in a fraction of a second, a temperature high enough to emit infrared radiation and allow the sensing material to react with gas molecules.

Many gas molecules absorb infrared. The amount of radiation absorbed allows the gas to be identified and its concentration calculated - the basic principle behind, for example, the roadside breathalyzer test. CCMOSS’s technology, however, is far more sensitive - using broadband infrared, the gas sensor can detect wavelengths between 2 and 14 micronmeters, corresponding to a wide range of biomarkers. In order to detect different wavelengths, a filter is placed over the detector so that only infrared radiation of a particular wavelength can get through.

The company, a spinout from the University of Cambridge Department of Engineering, has been supported by seed funding from Cambridge Enterprise, the University’s commercialization arm. The CCMOSS technology is being developed for use in noninvasive medical analysis and other applications such as consumer electronics, industrial security, and automotive applications. It currently has a range of products available and is actively involved in R&D projects for next generation micro- and nanosensors.

Related Links:

University of Cambridge
Cambridge CMOS Sensors (CCMOSS)



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: A microscope image of a neuron with inclusion (stained orange) caused by Huntington\'s disease (Photo courtesy of Wikimedia Commons).

Molecular Interactions Identified That Block Protein Transfer into Mitochondria of Huntington's Disease Neurons

Researchers have identified a protein complex that interacts with the mutated form of huntingtin protein to impair transport of proteins into the mitochondria of brain cells, which leads to their malfunction... Read more

Drug Discovery

view channel
Image: A mouse mammary gland missing the tumor-suppressor p53 shows expression of ARF (green), now known for a backup role in protecting cells from becoming cancerous. If both p53 and ARF are mutated, the tumors that form are aggressive and may benefit from treatment with anti-inflammatory drugs called JAK inhibitors, currently prescribed for rheumatoid arthritis (Photo courtesy of Raleigh Kladney).

Anti-Inflammatory Drugs May Treat Some Aggressive Rumors

New research raises the possibility that some cancer patients with aggressive tumors may benefit from a class of anti-inflammatory drugs used to treat rheumatoid arthritis. By studying triple-negative... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.